ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Formononetin attenuates ethanol-induced gastric ulcer injury by targeting ALDH2 to inhibit oxidative stress.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethanol-induced gastric ulceration is primarily driven by oxidative stress, mitochondrial dysfunction, and gastric epithelial cell injury. Although formononetin (Fmn), a naturally occurring isoflavone, possesses well-documented antioxidant and anti-inflammatory properties, its protective role and underlying molecular mechanisms in ethanol-induced gastric injury remain unclear. In this study, ethanol-treated GES-1 gastric epithelial cells were used as an in vitro model to investigate the cytoprotective effects of Fmn. Cell proliferation, apoptosis, oxidative stress, and mitochondrial function were evaluated using biochemical and cellular assays. Potential molecular targets were identified through SwissTargetPrediction and molecular docking, followed by experimental validation, including ALDH2 knockdown, qRT-PCR, and enzymatic activity assays. Fmn significantly attenuated ethanol-induced cellular injury by restoring cell proliferation, suppressing apoptosis, reducing intracellular and mitochondrial reactive oxygen species, decreasing malondialdehyde levels, and enhancing superoxide dismutase activity. Molecular docking demonstrated a strong binding affinity between Fmn and aldehyde dehydrogenase 2 (ALDH2), which was further confirmed by increased ALDH2 mRNA and protein expression as well as enhanced enzymatic activity following Fmn treatment. Functional studies revealed that ALDH2 upregulation plays a pivotal role in preserving mitochondrial integrity and limiting oxidative damage. Collectively, these findings demonstrate that Fmn protects gastric epithelial cells against ethanol-induced injury through ALDH2-mediated suppression of oxidative stress and mitochondrial dysfunction, highlighting its potential as a promising therapeutic candidate for the prevention and treatment of alcohol-induced gastric ulceration.
Indexed as
Identifiers
42844309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.